You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

JUNIOR STRENGTH MOTRIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Junior Strength Motrin patents expire, and what generic alternatives are available?

Junior Strength Motrin is a drug marketed by J And J Consumer Inc and is included in two NDAs.

The generic ingredient in JUNIOR STRENGTH MOTRIN is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and thirty-seven suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Junior Strength Motrin

A generic version of JUNIOR STRENGTH MOTRIN was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for JUNIOR STRENGTH MOTRIN?
  • What are the global sales for JUNIOR STRENGTH MOTRIN?
  • What is Average Wholesale Price for JUNIOR STRENGTH MOTRIN?
Summary for JUNIOR STRENGTH MOTRIN
Drug patent expirations by year for JUNIOR STRENGTH MOTRIN

US Patents and Regulatory Information for JUNIOR STRENGTH MOTRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc JUNIOR STRENGTH MOTRIN ibuprofen TABLET, CHEWABLE;ORAL 020601-003 Nov 15, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
J And J Consumer Inc JUNIOR STRENGTH MOTRIN ibuprofen TABLET;ORAL 020602-001 Jun 10, 1996 OTC No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for JUNIOR STRENGTH MOTRIN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Recordati Rare Diseases Pedea ibuprofen EMEA/H/C/000549
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.
Authorised no no no 2004-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for JUNIOR STRENGTH MOTRIN

See the table below for patents covering JUNIOR STRENGTH MOTRIN around the world.

Country Patent Number Title Estimated Expiration
Spain 2081349 ⤷  Sign Up
Greece 1001171 ΠΕΡΙΣΤΡΟΦΟΚΟΚΚΟΠΟΙΗΣΕΙΣ ΚΑΙ ΕΠΙΣΤΡΩΣΕΙΣ ΚΑΛΥΨΕΩΣ ΓΕΥΣΕΩΣ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΜΑΣΗΣΙΜΩΝ ΔΙΣΚΙΩΝ. (ROTOGRANULATIONS AND TASTE MASKING COATINGS FOR THE PREPARATION OF CHEWABLE TABLETS) ⤷  Sign Up
Ireland 902823 ⤷  Sign Up
Austria 129406 ⤷  Sign Up
Greece 900100587 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for JUNIOR STRENGTH MOTRIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1781277 PA2024501 Lithuania ⤷  Sign Up PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.